In this work, we found that by isolating EVs enriched from CD24+ and HER2+ EV sub-types, we can gain a more comprehensive view of a developing cancer than is possible with either single EV sub-population, and thus make more accurate clinical classifications. This evidence concerns the gene CD24 and cancer.